Advanced Oncotherapy PLC (AIM:AVO), developer of the LIGHT next-generation proton therapy system for cancer treatment, has announced findings of an important simulation study that suggests LIGHT will offer superiority in the treatment of breast cancer.
These results, coupled with the cost benefits of LIGHT over cyclotron-based proton therapy, build the case for the increased use of proton therapy for breast cancer patients, a large market that has the potential to be addressed by LIGHT.
The study has been reviewed by its research partner, the Cleveland Clinic, and is expected to be presented at a leading medical conference during 2023.
The findings from the simulation study imply that the LIGHT beam spot size, particularly LIGHT minibeams, is capable of delivering better results for organs at risk (OAR) preservation in patients with breast cancer while maintaining similar target coverage compared with legacy cyclotron treatment.
Dr. Jonathan Farr, chief clinical officer of Advanced Oncotherapy, said: "The findings show that the LIGHT proton system is ideally positioned to target such tumours while minimising damage to surrounding healthy tissues, in particular, the heart and lungs.
We look forward to presenting data from this simulation at a leading medical conference in 2023 and continuing to work with our research partners to illustrate the clinical advantages of our LIGHT system to patients."